Innate Pharma SA (IPHA) SEC filings

IPHANasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31Also trades as IPHYF

Financials through fiscal 2025, year ended Dec 31, 2025Last filing: 20-F on Apr 1, 2026Score 0/30

$1.49−0.10 (-6.29%)

Close on Nov 12, 2026Market cap $139.64MP/E –Yield –

SEC filings

40 of Innate Pharma's most recent filings on SEC EDGAR

Document	Form	Period	Filed	Source
Current report	6-K	Nov 11, 2026	Nov 12, 2026	SEC EDGAR
Current report	6-K	Nov 5, 2026	Nov 5, 2026	SEC EDGAR
Current report	6-K	Oct 27, 2026	Oct 27, 2026	SEC EDGAR
Current report	6-K	Oct 21, 2026	Oct 21, 2026	SEC EDGAR
Current report	6-K	Oct 20, 2026	Oct 20, 2026	SEC EDGAR
Current report	6-K	Sep 17, 2026	Sep 17, 2026	SEC EDGAR
Current report	6-K	Sep 16, 2026	Sep 17, 2026	SEC EDGAR
Current report	6-K	Jun 30, 2026	Sep 17, 2026	SEC EDGAR
Current report	6-K	Sep 10, 2026	Sep 10, 2026	SEC EDGAR
Current report	6-K	Sep 2, 2026	Sep 2, 2026	SEC EDGAR
Current report	6-K	Aug 19, 2026	Aug 19, 2026	SEC EDGAR
Current report	6-K	Aug 14, 2026	Aug 14, 2026	SEC EDGAR
Current report	6-K	Aug 10, 2026	Aug 10, 2026	SEC EDGAR
Current report	6-K	Jul 23, 2026	Jul 23, 2026	SEC EDGAR
Current report	6-K	Jul 21, 2026	Jul 21, 2026	SEC EDGAR
Current report	6-K	May 22, 2026	May 22, 2026	SEC EDGAR
Current report	6-K	May 19, 2026	May 19, 2026	SEC EDGAR
Current report	6-K	May 13, 2026	May 13, 2026	SEC EDGAR
Current report	6-K	May 12, 2026	May 12, 2026	SEC EDGAR
Current report	6-K	May 6, 2026	May 6, 2026	SEC EDGAR
Current report	6-K	Apr 23, 2026	Apr 23, 2026	SEC EDGAR
Current report	6-K	Apr 17, 2026	Apr 17, 2026	SEC EDGAR
Current report	6-K	Apr 13, 2026	Apr 13, 2026	SEC EDGAR
Current report	6-K	Apr 13, 2026	Apr 13, 2026	SEC EDGAR
Current report	6-K	Apr 8, 2026	Apr 8, 2026	SEC EDGAR
Current report	6-K	Apr 3, 2026	Apr 3, 2026	SEC EDGAR
Current report	6-K	Apr 2, 2026	Apr 2, 2026	SEC EDGAR
Annual report	20-F	Dec 31, 2025	Apr 1, 2026	SEC EDGAR
Current report	6-K	Mar 26, 2026	Mar 26, 2026	SEC EDGAR
Current report	6-K	Mar 19, 2026	Mar 19, 2026	SEC EDGAR
Current report	6-K	Feb 18, 2026	Feb 18, 2026	SEC EDGAR
Current report	6-K	Jan 7, 2026	Jan 7, 2026	SEC EDGAR
Current report	6-K	Dec 22, 2025	Dec 22, 2025	SEC EDGAR
Current report	6-K	Dec 11, 2025	Dec 11, 2025	SEC EDGAR
Current report	6-K	Nov 28, 2025	Nov 28, 2025	SEC EDGAR
Current report	6-K	Nov 17, 2025	Nov 17, 2025	SEC EDGAR
Current report	6-K	Nov 13, 2025	Nov 13, 2025	SEC EDGAR
Current report	6-K	Nov 10, 2025	Nov 10, 2025	SEC EDGAR
Current report	6-K	Nov 5, 2025	Nov 5, 2025	SEC EDGAR
Current report	6-K	Oct 14, 2025	Oct 15, 2025	SEC EDGAR

Where these numbers come from

Parsed from the XBRL in Innate Pharma's annual and quarterly filings with the SEC
Fourth quarters derived from the annual report minus nine months
Every figure in the statements links to its source filing

Against peers

Trailing twelve months. Peers are matched on business description, industry and size. Ticks are peers, the dot is IPHA.

Compare: IPHA vs MOLN · IPHA vs TCRX · IPHA vs EVAX · IPHA vs CRBU · IPHA vs CRIS

Revenue growth-55.2% · median -38.4%

Operating margin-599.8% · median -1140.6%

Company	Revenue	Growth
CRBU	$9.44M	+1.6%
IPHA	€9.01M	-55.2%
TCRX	$5.19M	-38.4%
CRIS	$4.31M	-62.2%
MOLN	–	–
EVAX	–	–

Company

Exchange: Nasdaq
Industry: Biological Products, (No Diagnostic Substances)
Fiscal year ends: December 31
Employees: 181
Auditor: Deloitte & Associes
SEC CIK: 1598599

Advertisement
300 × 250

See a number that looks wrong?